Literature DB >> 9595408

Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration.

M Kohno1, K Yokokawa, K Yasunari, H Kano, M Minami, J Yoshikawa.   

Abstract

The migration of coronary artery medial smooth-muscle cells (SMCs) is one of the key events in the process of intimal thickening in coronary atherosclerotic lesions. The objectives of the present study were to determine whether any of the three isoforms of endothelin (ET), ET-1, ET-2, and ET-3, or an intermediate form of ET, big ET-1, induces migration of human coronary artery SMCs, and to investigate the possible interaction of ET peptides and well-known migration-stimulatory factors, platelet-derived growth factor (PDGF)-BB and angiotensin II (Ang II), on SMC migration by the Boyden's chamber method. None of the ET peptides alone induced SMC migration between 10(-9) and 10(-7) mol/L. In contrast, ET-1 and ET-2 significantly induced SMC migration in the presence of low concentrations of PDGF-BB (0.5 ng/mL) or Ang II (10(-9) mol/L), although ET-3 was less active (ET-1 = ET-2 > ET-3). In contrast, big ET-1 was without significant activity on PDGF-BB-or Ang II-induced SMC migration. The potentiation of SMC migration by ET peptides was clearly inhibited by the ETA receptor antagonist BG-123 in a concentration-dependent manner. These results suggest that the ET family of peptides, especially ET-1 and ET-2, can induce human coronary artery SMC migration in combination with PDGF-BB or Ang II, probably via ETA receptors. Taken together with the finding that the concentrations of ET, PDGF-BB and Ang II are locally increased at sites of endothelial injury, this indicates that ET may be an initial stimulus for human coronary artery medial SMC recruitment during coronary atherosclerosis, possibly in combination with PDGF-BB or Ang II.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9595408     DOI: 10.1097/00005344-199800001-00027

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Endothelin-1 stimulates human colonic myofibroblast contraction and migration.

Authors:  L E Kernochan; B N Tran; P Tangkijvanich; A C Melton; S P Tam; H F Yee
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 3.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

4.  Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells.

Authors:  Georgia Kapakos; Ali Bouallegue; Grace Bou Daou; Ashok K Srivastava
Journal:  Curr Cardiol Rev       Date:  2010-11

5.  The Reducing Effects of Pyrogallol-Phloroglucinol-6,6-Bieckol on High-Fat Diet-Induced Pyroptosis in Endothelial and Vascular Smooth Muscle Cells of Mice Aortas.

Authors:  Seyeon Oh; Myeongjoo Son; Chul-Hyun Park; Ji Tae Jang; Kuk Hui Son; Kyunghee Byun
Journal:  Mar Drugs       Date:  2020-12-16       Impact factor: 5.118

Review 6.  Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; Shams Tabrez; Nasimudeen R Jabir; V Prakash Reddy; Yi Li; Geoffrey Burnstock; Ramon Cacabelos; Mohammad Amjad Kamal
Journal:  Oxid Med Cell Longev       Date:  2013-04-03       Impact factor: 6.543

7.  Minimally modified LDL upregulates endothelin type A receptors in rat coronary arterial smooth muscle cells.

Authors:  Jie Li; Lei Cao; Cang-Bao Xu; Jun-Jie Wang; Yong-Xiao Cao
Journal:  Mediators Inflamm       Date:  2013-06-19       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.